Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-8,292
Closed -$201K 145
2025
Q2
$201K Sell
8,292
-7,036
-46% -$164K 0.16% 123
2025
Q1
$388K Sell
15,328
-2,053
-12% -$53.7K 0.32% 89
2024
Q4
$461K Buy
17,381
+353
+2% +$9.57K 0.38% 86
2024
Q3
$493K Sell
17,028
-991
-5% -$28.9K 0.4% 85
2024
Q2
$504K Sell
18,019
-1,976
-10% -$54.4K 0.43% 77
2024
Q1
$555K Sell
19,995
-138
-0.7% -$3.83K 0.48% 68
2023
Q4
$580K Sell
20,133
-3,806
-16% -$115K 0.55% 58
2023
Q3
$794K Buy
23,939
+864
+4% +$30.6K 0.74% 44
2023
Q2
$846K Buy
23,075
+477
+2% +$18.6K 0.85% 38
2023
Q1
$934K Buy
22,598
+1,316
+6% +$56.8K 0.94% 30
2022
Q4
$1.09M Buy
21,282
+1,673
+9% +$80.2K 1.23% 18
2022
Q3
$866K Sell
19,609
-235
-1% -$11.4K 1.05% 22
2022
Q2
$1.04M Buy
19,844
+679
+4% +$34.6K 1.23% 18
2022
Q1
$922K Sell
19,165
-5,564
-22% -$289K 1.03% 21
2021
Q4
$1.32M Buy
+24,729
New +$1.23M 1.14% 20

Other funds holding PFE

DMC Group's PFE Position: Q3 2025 in Review

DMC Group sold out of Pfizer (PFE) in Q3 2025, closing a stake of 8,292 shares — an estimated $201K sold.

DMC Group first reported a position in PFE in Q4 2021 and held it in 15 quarters. The position peaked at $1.32M in Q4 2021. 2,811 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

  • DMC Group reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
  • DMC Group sold 8,292 Pfizer shares in Q3 2025, an estimated $201K.
  • DMC Group first reported a position in Pfizer in Q4 2021 and held it in 15 quarters.
  • DMC Group's Pfizer position peaked at $1.32M in Q4 2021.
  • 2,811 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on DMC Group's 13F filing for Q3 2025, filed 29 Oct 2025.